<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313167</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-595</org_study_id>
    <nct_id>NCT03313167</nct_id>
  </id_info>
  <brief_title>Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate</brief_title>
  <official_title>Systematic Screening for Atrial Fibrillation-potential Patients to Increase AF Detection Rate (SCAN-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the prevalence of all (prevalent and paroxysmal) undiagnosed atrial fibrillation
      (AF) in a Japanese population with a moderate-to-high risk of stroke
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Actual">May 23, 2019</completion_date>
  <primary_completion_date type="Actual">May 23, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects screened with AF identified at Index Visit</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of subjects screened with AF not identified at Index Visit</measure>
    <time_frame>Up to 4 weeks from Index Visit</time_frame>
    <description>number of subjects screened who have AF not identified at their Index Visit but subsequently found to have AF confirmed by 12-lead Electrocardiogram (ECG) during the extended monitoring period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of subjects with ECG-confirmed AF detected by the Omron BP device</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>number of subjects with ECG-confirmed AF detected by the Omron blood pressure (BP) device during the extended monitoring period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with ECG-confirmed AF detected by MB or HCG-801</measure>
    <time_frame>Day 14 to Day 28</time_frame>
    <description>number of subjects with ECG-confirmed AF detected by MyBeat (MB) or Omron HeartScan 801 (HCG-801) during the extended monitoring period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with AF identified at Index Visit who are prescribed guideline recommended anticoagulation therapy</measure>
    <time_frame>24 week follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with AF identified at their Index Visit who are prescribed guideline recommended anticoagulation therapy and still on the prescribed anticoagulation therapy at the end of the 24-week follow-up period</measure>
    <time_frame>At week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with Paroxysmal atrial fibrillation (PAF) identified during the extended monitoring period who are prescribed guideline-recommended anticoagulation therapy</measure>
    <time_frame>Day 1 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with PAF identified during the extended monitoring period who are prescribed guideline-recommended anticoagulation therapy and still on the prescribed anticoagulation therapy at the end of the 24-week follow-up</measure>
    <time_frame>At week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with AF identified at the Index Visit who had an ischemic stroke during the 24-week follow-up period</measure>
    <time_frame>Index Visit up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with PAF identified during the extended monitoring period who had an ischemic stroke during the 24-week follow-up period</measure>
    <time_frame>Day 1 up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with AF identified at the Index Visit who bled during the 24-week follow-up period</measure>
    <time_frame>Index Visit up to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects with PAF identified during the extended monitoring period who bled during the 24-week follow-up period</measure>
    <time_frame>Day 1 up to week 24</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1316</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial Fibrillation-potential Patients</arm_group_label>
    <description>individuals 65 years of age or older with moderate-to-high risk of stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>Non-interventional</description>
    <arm_group_label>Atrial Fibrillation-potential Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japanese population with a moderate-to high risk of stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 65 and one or more of the following: hypertension, prior stroke or transient
             ischemic attack, congestive heart failure, diabetes mellitus, and/or vascular disease

        Exclusion Criteria:

          -  Age &lt; 65 years, individuals with AF or a history of AF, or individuals taking
             anti-arrhythmic drugs

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

